Market Overview

Barclays Initiates Hilton Spin-Off Park Hotels At Overweight


Barclays started coverage of Park Hotels & Resorts Inc (NYSE: PK) with an Overweight rating and $30 price target, highlighting its cash flow and margin expansion opportunities.

“Park is a high cash flow generating lodging REIT with a meaningful margin expansion story over the next several quarters and with additional growth drivers (acquisitions, ROI projects) over the medium term,” analyst Anthony Powell wrote in a note.

Powell expects Park, which was spun-off from Hilton, to identify margin expansion opportunities this year and could potentially announce an acquisition by late 2017 or early 2018. The analyst estimates margin expansion opportunity could drive $3 in upside in shares if Park’s EBITDA margins reach its peers at 31 percent.

Park trades at a discount to its lodging REIT peers, including Sunstone Hotel Investors Inc (NYSE: SHO) and DiamondRock Hospitality Company (NYSE: DRH), on many metrics, with an estimated dividend yield of 6.9 percent that exceeds all 18 lodging REITs.  

Powell estimates dividend (a potential catalyst for the stock) of $1.88 for 2017, representing a dividend yield of 6.9 percent. This compares with the current lodging REIT dividend yield average of 5.2 percent.

“Park's moderate leverage and low cost of debt drives one of the highest fixed charge coverage ratios in our REIT coverage universe, allowing for high dividend payments,” Powell added.

At last check, shares of Park Hotels were up 0.88 percent to $27.58. The $30 price target represents potential upside of about 9 percent.

Latest Ratings for PK

Nov 2019MaintainsHold
Oct 2019MaintainsHold
Oct 2019Initiates Coverage OnMarket Perform

View More Analyst Ratings for PK
View the Latest Analyst Ratings

Posted-In: Anthony Powell BarclaysAnalyst Color Price Target Initiation Analyst Ratings


Related Articles (DRH + PK)

View Comments and Join the Discussion!

Latest Ratings

TORCCantor FitzgeraldDowngrades3.0
CIDMCanaccord GenuityMaintains1.5
TDGCanaccord GenuityMaintains620.0
DLPNCanaccord GenuityMaintains1.6
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Allergan's Chief R&D Officer Talks Avycaz, Assembly Biosciences And 6 'Potential Blockbusters' In The Pipeline

How The Market Performed The First Month Of Every Presidency Since Eisenhower